Michael Torres, Chief Executive Officer, CrossBridge Bio
From Innovation to Acquisition: CrossBridge Bio’s ADC Journey
“World ADC San Diego helped increase visibility for the program and provided a useful forum to share key elements of the dataset... that visibility supported ongoing discussions and ultimately contributed to the Lilly transaction.”
Read his interview to gain insights into the evolving ADC field and the future of dual-payload ADCs, following Eli Lilly’s $300m acquisition of CrossBridge Bio in April 2026.